Rezolute, Inc. (RZLT, Financial) is moving forward with its Phase 3 sunRIZE clinical trial as planned, following positive feedback from the Data Monitoring Committee (DMC). The committee conducted an interim analysis of the trial, which focuses on patients with congenital hyperinsulinism (HI), and recommended continuing without expanding the study's sample size.
The interim analysis was carried out by an unblinded DMC and concentrated on a pre-specified primary endpoint evaluation. This review occurred after roughly half of the study participants completed the main assessments. The goal of the analysis was to assess the study’s progress, particularly in determining if the trial might be futile or if adjustments in sample size were needed to bolster its statistical power and confidence in the final outcomes.
Rezolute has maintained a blinded status during the interim analysis, meaning it has not accessed the data reviewed by the DMC that informed its recommendation. The company also stated that it has not received any additional information from the DMC beyond the advice to proceed with the trial as initially planned.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Rezolute Inc (RZLT, Financial) is $13.00 with a high estimate of $16.00 and a low estimate of $9.00. The average target implies an upside of 318.01% from the current price of $3.11. More detailed estimate data can be found on the Rezolute Inc (RZLT) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Rezolute Inc's (RZLT, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
